Methylated circulating tumor DNA (Met-DNA) as an independent prognostic factor in metastatic pancreatic adenocarcinoma (mPAC) patients. - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Communication Dans Un Congrès Année : 2019

Methylated circulating tumor DNA (Met-DNA) as an independent prognostic factor in metastatic pancreatic adenocarcinoma (mPAC) patients.

JOURNAL OF CLINICAL ONCOLOGY Volume: 37 Issue: 15 Supplement: S Meeting Abstract: 4136 Published: MAY 20 2019

Fichier non déposé

Dates et versions

inserm-02413138 , version 1 (16-12-2019)

Identifiants

  • HAL Id : inserm-02413138 , version 1

Citer

D. Pietrasz, Shufang Wang-Renault, Laetitia Dahan, Julien Taieb, Karine Le Malicot, et al.. Methylated circulating tumor DNA (Met-DNA) as an independent prognostic factor in metastatic pancreatic adenocarcinoma (mPAC) patients.. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), May 2019, Chicago, United States. ⟨inserm-02413138⟩
36 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More